PD-1 and PD-L1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2017

DelveInsight‘s report, “PD-1 and PD-L1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2017” gives the comprehensive insights on the PD-1 and PD-L1 Inhibitors.

The report provides the analysis on the worldwide therapeutic market of PD-1 and PD-L1 inhibitors including information of Marketed molecules, detailed profiling of Pipeline assets and their pathways. The report covers the therapeutics assessment of pipeline molecules by the mechanism of action (MoA), route of administration (RoA), molecule type, along with latest updates. The report deals with the detailed epidemiology of all prevalent indications.

Report also covers other Commercial Aspects such as the Current and Future Market, Barriers and challenges, SWOT analysis. Report describes the possible unmet needs covered by PD-1 and PD-L1 inhibitors, highlighting the side effects and toxic effects related to PD-1 and PD-L1 inhibitors which are major concerns in the market for the usage of PD-1 and PD-L1 inhibitors.

The report throws light on the combinations therapies with Immune-check point Inhibitors (PD-1 and PD-L1) and provides information on ongoing collaborations for the development of combinations regimens.

Major active therapy areas include Metastatic Renal Cell Carcinoma, Squamous Cell Carcinomas of the Head and Neck, Metastatic Colorectal Cancer and Non-Small Cell lung cancer.

DelveInsight Analysis predicts that PD-1 and PD-L1 inhibitors are among the highly growing fields in the bio-pharmaceutical industry. Most of these immunotherapeutic are being used in Oncology. There are 50+ active drugs in the pipeline. Companies have also gone in collaboration with different partners like for evaluating their drugs in combination with Immune Checkpoint Inhibitors (PD-1/PD-L1). There are approximately 40 companies which are active in the development of different drugs targeting PD-1 and PD-L1.

The future competitive landscape of PD-1 and PD-L1 inhibitors is estimated to be very strong. There are 3 marketed products of PD-1 and PD-L1 inhibitors. Treatment options such as surgery, chemotherapy, radiation therapy, and many others are able to fulfill the current unmet need to an extent. With 7 drugs in the Phase III pipeline of the PD-1 and PD-L1 inhibitors, the market looks promising in coming years as well.

For more information please click here:
https://www.delveinsight.com/pd-1-and-pd-l1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2017-4186-p.php

About DelveInsight:
DelveInsight is a Business Consultant company and serves as a Knowledge partner across the value chain of Pharmaceutical Industry. With the use of proprietary databases and analytical models, DelveInsight provides cutting-edge market and pipeline analysis and API intelligence across all therapy areas to the Pharma and biotech sector, helping clients to quantify market events and evaluate their impact on the valuation of products, portfolios, and companies.

DelveInsight business research,
A20, Sector 7, Near to Maxfort. School,
Dwarka

New Delhi-110077, India

Tel: +91-11-4568 9769 | +91 9650213330

This release was published on openPR.